2Seventy Bio Inc
NASDAQ:TSVT

Watchlist Manager
2Seventy Bio Inc Logo
2Seventy Bio Inc
NASDAQ:TSVT
Watchlist
Price: 4.99 USD Market Closed
Market Cap: 261.2m USD

Operating Margin
2Seventy Bio Inc

-260.4%
Current
-299%
Average
-5.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-260.4%
=
Operating Profit
-98.6m
/
Revenue
37.9m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
2Seventy Bio Inc
NASDAQ:TSVT
257.4m USD
-260%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
344.4B USD
29%
US
Amgen Inc
NASDAQ:AMGN
156.2B USD
22%
US
Gilead Sciences Inc
NASDAQ:GILD
132.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.9B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
122.2B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.6B EUR
-1%

2Seventy Bio Inc
Glance View

Market Cap
257.4m USD
Industry
Biotechnology

2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.

TSVT Intrinsic Value
3.44 USD
Overvaluation 31%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-260.4%
=
Operating Profit
-98.6m
/
Revenue
37.9m
What is the Operating Margin of 2Seventy Bio Inc?

Based on 2Seventy Bio Inc's most recent financial statements, the company has Operating Margin of -260.4%.

Back to Top